文献速递肺血管病与心包/心肌炎

溶栓治疗对中危肺栓塞长期结局的影响

Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

PEITHO试验长期随访纳入709例中危肺栓塞患者,比较替奈普酶溶栓与安慰剂。中位随访37.8个月,溶栓组与安慰剂组全因死亡率分别为20.3%与18.0%(p=0.43),持续性呼吸困难或功能受限分别为36.0%与30.1%(p=0.23),慢性血栓栓塞性肺动脉高压(CTEPH)分别为2.1%与3.2%(p=0.79)。溶栓未影响长期死亡率,也未减少残余呼吸困难或右心室功能障碍。

要点

  • 中危肺栓塞后约33%患者存在不同程度的持续性功能受限,但CTEPH不常见。
  • 溶栓组与安慰剂组长期全因死亡率分别为20.3%与18.0%,差异无统计学意义(p=0.43)。
  • 溶栓未显著减少残余呼吸困难或右心室功能障碍,CTEPH发生率两组相近。

核心结论

  • 约33%的中危肺栓塞患者报告存在某种程度的持续性功能受限,但CTEPH不常见。
  • 溶栓治疗未影响长期死亡率,也未减少残余呼吸困难或右心室功能障碍。

研究设计与样本

  • PEITHO试验为随机(1:1)对照研究,比较替奈普酶溶栓与安慰剂,纳入血压正常、影像学有右心室功能障碍且心肌肌钙蛋白阳性的急性肺栓塞患者,两组均接受标准抗凝治疗。
  • 长期随访纳入第三次方案修订,28个中心参与,随机分配了1006例患者中的709例。

主要发现

  • 长期(中位37.8个月)生存评估在溶栓组359例中完成353例(98.3%),安慰剂组350例中完成343例(98.0%)。
  • 总死亡率溶栓组为20.3%,安慰剂组为18.0%(p=0.43)。
  • 第30天至长期随访期间,溶栓组死亡65例,安慰剂组死亡53例。
  • 随访存活者中,持续性呼吸困难(多为轻度)或功能受限溶栓组报告36.0%,安慰剂组报告30.1%(p=0.23)。
  • 超声心动图(溶栓组144例、安慰剂组146例)未显示残余肺动脉高压或右心室功能障碍的显著差异;确诊CTEPH溶栓组4例(2.1%),安慰剂组6例(3.2%)(p=0.79)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. OBJECTIVES: This study investigated the long-term prognosis of patients with intermediate-risk PE and the effect of thrombolytic treatment on the persistence of symptoms or the development of late complications. METHODS: The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normotensive patients with acute PE, right ventricular (RV) dysfunction on imaging, and a positive cardiac troponin test result. Both treatment arms received standard anticoagulation. Long-term follow-up was included in the third protocol amendment; 28 sites randomizing 709 of the 1,006 patients participated. RESULTS: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. Overall mortality rates were 20.3% and 18.0%, respectively (p = 0.43). Between day 30 and long-term follow-up, 65 deaths occurred in the thrombolysis arm and 53 occurred in the placebo arm. At follow-up examination of survivors, persistent dyspnea (mostly mild) or functional limitation was reported by 36.0% versus 30.1% of the patients (p = 0.23). Echocardiography (performed in 144 and 146 patients randomized to thrombolysis and placebo, respectively) did not reveal significant differences in residual pulmonary hypertension or RV dysfunction. Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%) versus 6 (3.2%) cases (p = 0.79). CONCLUSIONS: Approximately 33% of patients report some degree of persistent functional limitation after intermediate-risk PE, but CTEPH is infrequent. Thrombolytic treatment did not affect long-term mortality rates, and it did not appear to reduce residual dyspnea or RV dysfunction in these patients. (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639743).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Konstantinides SV, Vicaut E, Danays T, et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017. PMID: 28335835. doi:10.1016/j.jacc.2016.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。